| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Accelerating early drug development: come on down under!
|
Wei, A.H.
|
|
|
28 |
7 |
p. 1655-1657
|
artikel
|
| 2 |
Androgen receptor gene status in plasma DNA associates with worse outcome on enzalutamide or abiraterone for castration-resistant prostate cancer: a multi-institution correlative biomarker study
|
Conteduca, V.
|
|
|
28 |
7 |
p. 1508-1516
|
artikel
|
| 3 |
A prospective examination of circulating tumor cell profiles in non-small-cell lung cancer molecular subgroups
|
Lindsay, C.R.
|
|
|
28 |
7 |
p. 1523-1531
|
artikel
|
| 4 |
A randomized phase II/III study of cabazitaxel versus vinflunine in metastatic or locally advanced transitional cell carcinoma of the urothelium (SECAVIN)
|
Bellmunt, J.
|
|
|
28 |
7 |
p. 1517-1522
|
artikel
|
| 5 |
Assessing treatment efficacy in the subset of responders in a randomized clinical trial
|
Korn, E.L.
|
|
|
28 |
7 |
p. 1640-1647
|
artikel
|
| 6 |
A systems approach identifies time-dependent associations of multimorbidities with pancreatic cancer risk
|
Gomez-Rubio, P.
|
|
|
28 |
7 |
p. 1618-1624
|
artikel
|
| 7 |
Avelumab: clinical trial innovation and collaboration to advance anti-PD-L1 immunotherapy
|
Chin, K.
|
|
|
28 |
7 |
p. 1658-1666
|
artikel
|
| 8 |
Burnout among young European oncologists: a call for action
|
Blanchard, P.
|
|
|
28 |
7 |
p. 1414-1415
|
artikel
|
| 9 |
Cancer immunotherapy trial registrations increase exponentially but chronic immunosuppressive glucocorticoid therapy may compromise outcomes
|
Connell, C.M.
|
|
|
28 |
7 |
p. 1678-1679
|
artikel
|
| 10 |
Characteristics, outcomes, prognostic factors and treatment of patients with T-cell prolymphocytic leukemia (T-PLL)
|
Jain, P.
|
|
|
28 |
7 |
p. 1554-1559
|
artikel
|
| 11 |
CHD1: a new treatment biomarker for recombination deficiency in castration resistant prostate cancer?
|
Helleday, T.
|
|
|
28 |
7 |
p. 1407-1408
|
artikel
|
| 12 |
CHD1 loss sensitizes prostate cancer to DNA damaging therapy by promoting error-prone double-strand break repair
|
Shenoy, T.R.
|
|
|
28 |
7 |
p. 1495-1507
|
artikel
|
| 13 |
Clinical, pathological, and demographic factors associated with development of recurrences after surgical resection in elderly patients with neuroendocrine tumors
|
Shen, C.
|
|
|
28 |
7 |
p. 1582-1589
|
artikel
|
| 14 |
Clinical validation of a prognostic tool in a population of outpatients treated for incurable cancer undergoing anticancer therapy: PRONOPALL study
|
Bourgeois, H.
|
|
|
28 |
7 |
p. 1612-1617
|
artikel
|
| 15 |
Copy number alterations assessed at the single-cell level revealed mono- and polyclonal seeding patterns of distant metastasis in a small-cell lung cancer patient
|
Ferronika, P.
|
|
|
28 |
7 |
p. 1668-1670
|
artikel
|
| 16 |
Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study
|
Long, G.V.
|
|
|
28 |
7 |
p. 1631-1639
|
artikel
|
| 17 |
Diffuse large B-cell lymphoma (DLBCL), 2 versus 3: end of a debate?
|
Sarkozy, C.
|
|
|
28 |
7 |
p. 1411-1413
|
artikel
|
| 18 |
Editorial board
|
|
|
|
28 |
7 |
p. ii-iii
|
artikel
|
| 19 |
Efficacy of everolimus plus octreotide LAR in patients with advanced neuroendocrine tumor and carcinoid syndrome: final overall survival from the randomized, placebo-controlled phase 3 RADIANT-2 study
|
Pavel, M.E.
|
|
|
28 |
7 |
p. 1569-1575
|
artikel
|
| 20 |
Feasibility of allogeneic stem-cell transplantation after azacitidine bridge in higher-risk myelodysplastic syndromes and low blast count acute myeloid leukemia: results of the BMT-AZA prospective study
|
Voso, M.T.
|
|
|
28 |
7 |
p. 1547-1553
|
artikel
|
| 21 |
Genetic variations in cancer-related significantly mutated genes and lung cancer susceptibility
|
Zhang, Y.
|
|
|
28 |
7 |
p. 1625-1630
|
artikel
|
| 22 |
Glioblastoma targeted therapy: updated approaches from recent biological insights
|
Touat, M.
|
|
|
28 |
7 |
p. 1457-1472
|
artikel
|
| 23 |
Hyperprogression during anti-PD-1/PD-L1 therapy in patients with recurrent and/or metastatic head and neck squamous cell carcinoma
|
Saâda-Bouzid, E.
|
|
|
28 |
7 |
p. 1605-1611
|
artikel
|
| 24 |
Identifying an early indicator of drug efficacy in patients with metastatic colorectal cancer—a prospective evaluation of circulating tumor cells, 18F-fluorodeoxyglucose positron-emission tomography and the RECIST criteria
|
Ma, B.
|
|
|
28 |
7 |
p. 1576-1581
|
artikel
|
| 25 |
Idiopathic thrombocytopenic purpura and autoimmune neutropenia induced by prolonged use of nivolumab in Hodgkin’s lymphoma
|
Bulbul, A.
|
|
|
28 |
7 |
p. 1675-1676
|
artikel
|
| 26 |
Immune checkpoint inhibitors in advanced renal cell carcinoma: experience to date and future directions
|
Atkins, M.B.
|
|
|
28 |
7 |
p. 1484-1494
|
artikel
|
| 27 |
Impact of baseline BMI and weight change in CCTG adjuvant breast cancer trials
|
Yerushalmi, R.
|
|
|
28 |
7 |
p. 1560-1568
|
artikel
|
| 28 |
International Working Group consensus response evaluation criteria in lymphoma (RECIL 2017)
|
Younes, A.
|
|
|
28 |
7 |
p. 1436-1447
|
artikel
|
| 29 |
Intratumoral heterogeneity: pathways to treatment resistance and relapse in human glioblastoma
|
Qazi, M.A.
|
|
|
28 |
7 |
p. 1448-1456
|
artikel
|
| 30 |
irRECIST and iRECIST: the devil is in the details
|
Le Lay, J.
|
|
|
28 |
7 |
p. 1676-1678
|
artikel
|
| 31 |
Kaposi sarcoma in a patient treated with ruxolitinib
|
Loscocco, G.G.
|
|
|
28 |
7 |
p. 1670-1671
|
artikel
|
| 32 |
Lethal aplastic anemia caused by dual immune checkpoint blockade in metastatic melanoma
|
Helgadottir, H.
|
|
|
28 |
7 |
p. 1672-1673
|
artikel
|
| 33 |
Liquid biopsies and plasma DNA: paving the way for personalized medicine in metastatic castration-resistant prostate cancer
|
van Soest, R.J.
|
|
|
28 |
7 |
p. 1408-1409
|
artikel
|
| 34 |
Molecular classification of pulmonary sarcomatoid carcinomas suggests new therapeutic opportunities
|
Pécuchet, N.
|
|
|
28 |
7 |
p. 1597-1604
|
artikel
|
| 35 |
New European Clinical Trial Regulation: perception and expectations in Italy
|
Cagnazzo, C.
|
|
|
28 |
7 |
p. 1648-1654
|
artikel
|
| 36 |
Outcome of elderly patients with diffuse large B-cell lymphoma treated with R-CHOP: results from the UK NCRI R-CHOP14v21 trial with combined analysis of molecular characteristics with the DSHNHL RICOVER-60 trial
|
Kühnl, A.
|
|
|
28 |
7 |
p. 1540-1546
|
artikel
|
| 37 |
Professional burnout in European young oncologists: results of the European Society for Medical Oncology (ESMO) Young Oncologists Committee Burnout Survey
|
Banerjee, S.
|
|
|
28 |
7 |
p. 1590-1596
|
artikel
|
| 38 |
Pulmonary sarcomatoid carcinoma—a new hope
|
Boland, J.M.
|
|
|
28 |
7 |
p. 1417-1418
|
artikel
|
| 39 |
Statistical controversies in clinical research: building the bridge to phase II—efficacy estimation in dose-expansion cohorts
|
Boonstra, P.S.
|
|
|
28 |
7 |
p. 1427-1435
|
artikel
|
| 40 |
Statistical controversies in clinical research: futility analyses in oncology–lessons on potential pitfalls from a randomized controlled trial
|
Lesaffre, E.
|
|
|
28 |
7 |
p. 1419-1426
|
artikel
|
| 41 |
Structural and functional intratumor heterogeneities in glioblastoma: a spacetime odyssey at single-cell level
|
Idbaih, A.
|
|
|
28 |
7 |
p. 1415-1417
|
artikel
|
| 42 |
Systemic inflammatory reaction syndrome during combined kinase inhibitor therapy following anti-PD-1 therapy for melanoma
|
Urosevic-Maiwald, M.
|
|
|
28 |
7 |
p. 1673-1675
|
artikel
|
| 43 |
Table of Contents
|
|
|
|
28 |
7 |
p. iv-vii
|
artikel
|
| 44 |
The clinical impact of an EML4-ALK variant on survival following crizotinib treatment in patients with advanced ALK-rearranged non-small-cell lung cancer
|
Seo, S.
|
|
|
28 |
7 |
p. 1667-1668
|
artikel
|
| 45 |
Toward common response evaluation criteria for solid tumors and lymphomas: RECIL and RECIST?
|
Ribrag, V.
|
|
|
28 |
7 |
p. 1409-1411
|
artikel
|
| 46 |
Tumor immune microenvironment and nivolumab efficacy in EGFR mutation-positive non-small-cell lung cancer based on T790M status after disease progression during EGFR-TKI treatment
|
Haratani, K.
|
|
|
28 |
7 |
p. 1532-1539
|
artikel
|
| 47 |
What treatment in 2017 for inoperable pancreatic cancers?
|
Taieb, J.
|
|
|
28 |
7 |
p. 1473-1483
|
artikel
|
Tijdschrift beschrijving